SWOG


Also found in: Acronyms, Wikipedia.

SWOG

Southwestern Oncology Group

Southwest Oncology Group

,

SWOG

A clinical cooperative composed of cancer institutions in the southwestern U.S. that researches the value of innovation in treating and preventing cancer.
References in periodicals archive ?
The activity of GEM as a single-agent therapy was assessed in a phase II trial by SWOG in patients with recurrent or metastatic SCCHN.
This SWOG study is expected to give us a definitive answer to the following question: 'Does changing cancer therapy when CTCs are elevated make a difference in the survival of patients with metastatic breast cancer?
Albain's colleagues have conducted similar analyses for all of the other major cancers in the SWOG database.
Sequenta announced last week the inclusion of LymphoSIGHT[TM] in the SWOG S1106 Mantle cell lymphoma clinical trial to measure MRD.
MVAC rejimi ile elde edilen patolojik tam yanit orani (pT0) %38 olmustur (%38'e karsi %15, p=0,001) ve pT0 elde edilen olgularda 5-yillik sagkalim oraninin %85'e ulasmasi SWOG 8710 calismasinin etkileyici bir verisi olarak dikkati cekmektedir (17).
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
Results of this study, led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI), demonstrate that intermittent androgen-deprivation (AD) therapy is not as good as continuous hormone therapy with regard to patient longevity.
The physicians participate in NCI-sponsored clinical research with SWOG, ECOG, CALGB, CTSU, University of Chicago, and MD Anderson Cancer Center, and actively collaborate with others in the community in providing multidisciplinary quality cancer care at Memorial Medical Center and St.
According to a PGJDC official the decision to develop hallmarking in Pakistan is part of national strategy submitted by SWOG and Ministry of Industrys support.
The SWOG researchers also tracked complications prospectively.
The Phase II SWOG 8037 trial demonstrated the potential benefit of neoadjuvant chemoradiotherapy with 17% of the patients showing a pathological complete response [17].
The SWOG 8814 study was a Phase III RCT of postmenopausal, node-positive, ER-positive breast cancer patients randomly assigned to one of three treatment arms: tamoxifen 5years, cyclophosphamide, adriamycin, 5-fluorouracil (CAF) chemotherapy concurrently or CAF sequentially with tamoxifen.